PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-30

Study Completion Date

2029-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

NCT06664021

Intrahepatic Cholangiocarcinoma

RECRUITING PHASE2

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

NCT05407519

Hepatocellular Carcinoma

RECRUITING PHASE2

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

NCT02924376

Cholangiocarcinoma

COMPLETED PHASE2

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

NCT05156788

Biliary Tract Cancer PD-1 Antibody Gemox +1 more

UNKNOWN PHASE2

Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

NCT02591030

Bile Duct Cancer

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intrahepatic Cholangiocarcinoma (Icc)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CISGEM + Rilvegostomig

RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks 750 mg IV administration over 60 minutes (up to a total of 90 minutes).

CISGEM: For each cycle administration at D1 and D8 every 3 weeks

* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %
* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %

Group Type EXPERIMENTAL

CISGEM + Rilvegostomig

Intervention Type DRUG

Administration of 4 cycles pre-operative and 4 cycles post-operative of Cisplatine associated to Gemcitabine with rilvegostomig

RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks

• 750 mg IV administration over 60 minutes (up to a total of 90 minutes). CISGEM: For each cycle administration at D1 and D8 every 3 weeks

* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %
* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CISGEM + Rilvegostomig

Administration of 4 cycles pre-operative and 4 cycles post-operative of Cisplatine associated to Gemcitabine with rilvegostomig

RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks

• 750 mg IV administration over 60 minutes (up to a total of 90 minutes). CISGEM: For each cycle administration at D1 and D8 every 3 weeks

* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %
* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years
2. WHO Performance Status 0-1
3. Body weight \> 30kg
4. Histo/cytologically proven intrahepatic cholangiocarcinoma.
5. Measurable disease as defined by RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors).
6. Naive to systemic treatment and loco regional treatment for biliary tract cancer
7. At least one of the following high-risk criteria of post resection relapse:

* Tumor Size ≥ 50 mm and/or multiple nodules
* cN+
* Risk of narrow margin (\< 10 mm)
* Macrovascular invasion
8. Adequate organ function, as defined by the following:

* Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 2,5 x Upper Limit of Normal (ULN)
* Total serum bilirubin ≤ 1.5 ULN This will not apply to patients with confirmed Gilbert's syndrome
* Prothrombin ratio \> 70 % and/or Factor V \> 70 % in case of oral anticoagulation therapy
* Serum albumin ≥ 30 g/L
* Haemoglobin ≥ 10 g/dl and no transfusion within 4 weeks before inclusion
* Absolute Neutrophil Count (ANC) ≥ 1.5 G/L
* Platelets ≥ 150 G/L
9. Creatinine clearance ≥ 45 ml/min (calculated by CKD - EPI formula)
10. Life expectancy ≥ 3 months
11. Female postmenopausal for at least one year or surgically infertile for at least 6 weeks, or highly effective contraception for male and female patients of childbearing potential for the duration of study and for 7 months after the last dose of drug for female and 4 months for male.
12. A negative pregnancy test for inclusion for all female patients of child-bearing potential.
13. Patient covered by a plan of the French Social Security system.
14. Written informed consent obtained from the patient prior to performing any protocol-related procedures
15. Patient with available tumor tissue sample for the study or willing to have a biopsy

Exclusion Criteria

1. Existence of metastases or distant lymph node involvement considered as metastatic
2. Locally advanced disease considered as definitively non resectable
3. Cirrhosis with Child Pugh ≥ B7

1. Any history of liver decompensation: hepatic encephalopathy, presence of ascites
2. Presence of clinically significant portal hypertension (platelets counts \< 150G/L and/or liver stiffness \> 20kPa and/or presence of oesophageal and/or gastric varices)
4. Mixed histology (hepatocholangiocarcinoma)
5. Persistent toxicities (\> grade 2 NCI-CTCAE version 5.0) caused by previous cancer therapy.
6. Contraindication to immunotherapy: Active or prior documented autoimmune or inflammatory disorders or any severe or uncontrolled systemic disease
7. Current or prior use of immunosuppressive medication within 14 days before the first dose of protocol treatment
8. History of allogenic organ transplantation
9. Known or suspected allergy or hypersensitivity to any of the study drugs or any of the study drug excipients (cisplatin, gemcitabine and Rilvegostomig)
10. Live vaccine administration within 30 days prior to the first dose of study treatment Note: Patients, if enrolled, should not receive live vaccine whilst receiving investigational product and up to 6 months after the last dose of investigational product.
11. Uncontrolled infection with human immunodeficiency virus (HIV). Required conditions for inclusion are as follows: undetectable viral RNA, CD4+ count ≥350 cells/μL no history of AIDS-defining opportunistic infection within the past 12 months, stable condition for at least 4 weeks on the same anti-HIV medications.
12. Active and untreated infection with hepatitis B and/or hepatitis C Note: Patients with past HBV infection or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antigen \[HBc\] antibody test) are eligible.
13. Other active cancer or history of cancer within 2 years, except for carcinoma in situ of the cervix or basal cell or squamous cell skin carcinoma or any other carcinoma in situ, considered cured
14. History of clinically significant arrhythmia, cardiomyopathy of any etiology; symptomatic congestive heart failure (as defined by New York Heart Association class ≥ 3), history of myocardial infarction within the past 6 months. Participation in another clinical study with an investigational product during the last 4 weeks
15. Pregnant or breastfeeding woman.
16. Person deprived of liberty or under guardianship or incapable of giving consent
17. Inability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No